Cardiovascular

PUBLISHER: Knowledge Sourcing Intelligence | PRODUCT CODE: 2068216

PUBLISHER: Knowledge Sourcing Intelligence | PRODUCT CODE: 2068216

Coronary Angioplasty Market - Strategic Insights and Forecasts (2026-2031)

PUBLISHED: May 27, 2026

PAGES: 150 Pages

DELIVERY TIME: 1-2 business days

ADD TO COMPARE

SELECT AN OPTION

Description

The Global Coronary Angioplasty Market is forecast to grow at a CAGR of 5.9%, reaching USD 37.3 billion in 2031 from USD 28.0 billion in 2026.

The global coronary angioplasty market is witnessing stable growth due to the increasing prevalence of coronary artery disease, rising aging populations, and growing adoption of minimally invasive cardiovascular procedures. Coronary angioplasty has become a widely preferred treatment option for restoring blood flow in blocked coronary arteries because of its reduced recovery time, lower procedural risk, and improved patient outcomes compared to traditional surgical interventions. Expanding healthcare infrastructure, increasing awareness regarding early cardiac treatment, and advancements in interventional cardiology technologies are further supporting market expansion across developed and emerging healthcare systems.

Market Drivers

The growing burden of cardiovascular diseases remains a major factor driving the coronary angioplasty market. Rising incidence of hypertension, obesity, diabetes, and sedentary lifestyles is contributing to increasing cases of coronary artery disease globally. As healthcare providers focus on early intervention and effective cardiovascular treatment, demand for angioplasty procedures continues to rise across hospitals and specialty cardiac centers.

Technological advancements in angioplasty devices are also supporting market growth. Drug-eluting stents, bioresorbable vascular scaffolds, and advanced balloon catheter systems are improving procedural success rates and reducing complications such as restenosis. The increasing use of imaging-guided interventions and robotic-assisted angioplasty systems is further enhancing precision and clinical efficiency during coronary procedures.

Growing preference for minimally invasive procedures among patients and healthcare providers is accelerating market adoption. Coronary angioplasty offers shorter hospital stays, reduced post-operative complications, and faster patient recovery, making it an increasingly preferred treatment option for coronary artery blockages.

Expansion of healthcare access and rising investment in cardiac care infrastructure across emerging economies are also contributing to higher procedural volumes and broader availability of interventional cardiology services.

Market Restraints

High procedure costs and limited affordability in developing healthcare markets remain key challenges for the coronary angioplasty market. Advanced stent systems, imaging technologies, and specialized catheter devices can significantly increase treatment expenses for healthcare providers and patients.

Risk of procedural complications such as thrombosis, bleeding, arterial damage, and restenosis may also affect patient outcomes and increase the need for follow-up treatment. Stringent regulatory approval requirements for interventional cardiology devices can further increase product development timelines and operational costs for manufacturers.

Limited availability of skilled interventional cardiologists and specialized cardiac centers in underserved regions may restrict market growth in certain countries.

Technology and Segment Insights

Drug-eluting stents continue to represent the dominant product segment due to their ability to reduce arterial re-narrowing and improve long-term treatment outcomes. Balloon angioplasty catheters and guidewires also remain essential components of coronary intervention procedures.

Imaging-guided angioplasty technologies, including intravascular ultrasound and optical coherence tomography systems, are gaining traction because they improve procedural accuracy and lesion assessment. Robotic-assisted angioplasty systems are also emerging as an important technological advancement in complex coronary interventions.

By end user, hospitals remain the leading segment due to high patient volumes and advanced interventional cardiology infrastructure. Specialty cardiac centers and ambulatory surgical centers are also witnessing increasing demand as outpatient cardiovascular procedures continue to expand globally.

Competitive and Strategic Outlook

The market includes major cardiovascular device manufacturers and specialized interventional cardiology companies competing through product innovation, clinical performance, and geographic expansion strategies. Companies are investing in next-generation stent technologies, minimally invasive procedural systems, and AI-assisted imaging platforms to strengthen competitive positioning.

Strategic partnerships, acquisitions, and clinical research collaborations are becoming increasingly common across the industry. Manufacturers are also focusing on expanding distribution networks and improving affordability of angioplasty devices in emerging healthcare markets.

Conclusion

The global coronary angioplasty market is expected to witness sustained growth through 2031, supported by rising cardiovascular disease prevalence, increasing adoption of minimally invasive cardiac procedures, and continuous advancements in interventional cardiology technologies. Imaging-guided interventions, advanced stent systems, and robotic-assisted procedures will continue to shape market development. Companies focusing on innovation, procedural efficiency, and accessible cardiovascular care solutions are likely to strengthen their long-term market position.

Key Benefits of this Report

Insightful Analysis: Gain detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

Historical data from 2021 to 2024 and forecast data from 2026 to 2031
Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
Competitive positioning, strategies, and market share evaluation
Revenue growth and forecast assessment across segments and regions
Company profiling including strategies, products, financials, and key developments

Product Code: KSI-008672

1. Executive Summary

1.1 Market Snapshot
- 1.1.1 Global Coronary Angioplasty Market Overview
- 1.1.2 Market Size and Forecast Summary
- 1.1.3 Key Growth Drivers
- 1.1.4 Major Market Challenges
- 1.1.5 Technological Advancements in Coronary Angioplasty
- 1.1.6 Competitive Landscape Snapshot
- 1.1.7 Key Strategic Developments
1.2 Executive Insights
- 1.2.1 Adoption Trends of Drug-Eluting Technologies
- 1.2.2 Shift Toward Minimally Invasive Coronary Interventions
- 1.2.3 Outpatient and Ambulatory PCI Trends
- 1.2.4 Emerging Market Expansion Opportunities
- 1.2.5 AI and Imaging Integration in Interventional Cardiology

2. Disease & Epidemiology Analysis

2.1 Overview of Coronary Artery Disease (CAD)
- 2.1.1 Definition and Pathophysiology
- 2.1.2 Atherosclerosis Progression Mechanism
- 2.1.3 Clinical Manifestations of CAD
- 2.1.4 Stable Ischemic Heart Disease
- 2.1.5 Acute Coronary Syndrome (ACS)
2.2 Epidemiology of Coronary Artery Disease
- 2.2.1 Global CAD Burden
- 2.2.2 Prevalence by Age Group
- 2.2.3 Prevalence by Gender
- 2.2.4 Mortality and Morbidity Trends
- 2.2.5 Risk Factor Analysis
2.3 Epidemiology of Percutaneous Coronary Intervention (PCI)
- 2.3.1 PCI Procedure Volume Analysis
- 2.3.2 Elective vs Emergency Angioplasty Trends
- 2.3.3 Single-Vessel vs Multi-Vessel Intervention Trends
- 2.3.4 Repeat Revascularization Rates
- 2.3.5 Restenosis Incidence Analysis
2.4 Disease Burden by Clinical Indication
- 2.4.1 Stable Angina
- 2.4.2 ST-Elevation Myocardial Infarction (STEMI)
- 2.4.3 Non-ST-Elevation Myocardial Infarction (NSTEMI)
- 2.4.4 Chronic Total Occlusion (CTO)
- 2.4.5 Left Main Coronary Artery Disease
2.5 Clinical Guidelines and Treatment Algorithms
- 2.5.1 ACC/AHA PCI Guidelines
- 2.5.2 ESC Revascularization Guidelines
- 2.5.3 Japanese Circulation Society Recommendations
- 2.5.4 Indian Cardiological Society Recommendations

3. Market Dynamics

3.1 Market Drivers
- 3.1.1 Rising Global Burden of Cardiovascular Diseases
- 3.1.2 Increasing Adoption of Drug-Eluting Stents
- 3.1.3 Advancements in Imaging-Guided PCI
- 3.1.4 Expansion of Catheterization Laboratories
- 3.1.5 Growth in Geriatric Population
3.2 Market Restraints
- 3.2.1 High Procedure Costs
- 3.2.2 Risk of Restenosis and Stent Thrombosis
- 3.2.3 Stringent Regulatory Approval Pathways
- 3.2.4 Limited Access in Low-Income Regions
3.3 Market Opportunities
- 3.3.1 Bioabsorbable Scaffold Development
- 3.3.2 Robotic-Assisted PCI Systems
- 3.3.3 AI-Based Coronary Imaging and Navigation
- 3.3.4 Growth of Same-Day Discharge PCI
3.4 Market Challenges
- 3.4.1 Product Recalls and Safety Concerns
- 3.4.2 Pricing Pressure and Reimbursement Constraints
- 3.4.3 Physician Training Requirements
- 3.4.4 Complex Coronary Lesion Management
3.5 Porter's Five Forces Analysis
- 3.5.1 Bargaining Power of Suppliers
- 3.5.2 Bargaining Power of Buyers
- 3.5.3 Threat of New Entrants
- 3.5.4 Threat of Substitutes
- 3.5.5 Competitive Rivalry
3.6 PESTLE Analysis
- 3.6.1 Political Factors
- 3.6.2 Economic Factors
- 3.6.3 Social Factors
- 3.6.4 Technological Factors
- 3.6.5 Legal Factors
- 3.6.6 Environmental Factors

4. Commercial & Market Access

4.1 Market Access Overview
- 4.1.1 Reimbursement Landscape for PCI Procedures
- 4.1.2 Public vs Private Coverage Trends
- 4.1.3 Bundled Payment Models
4.2 Pricing Analysis
- 4.2.1 Drug-Eluting Stent Pricing Trends
- 4.2.2 Balloon Catheter Pricing Analysis
- 4.2.3 Imaging Catheter Pricing Trends
- 4.2.4 Regional Pricing Variability
4.3 Procurement and Distribution Trends
- 4.3.1 Hospital Procurement Models
- 4.3.2 Group Purchasing Organizations (GPOs)
- 4.3.3 Distributor and Direct Sales Models
4.4 Healthcare Infrastructure Assessment
- 4.4.1 Catheterization Laboratory Expansion
- 4.4.2 Availability of Interventional Cardiologists
- 4.4.3 Ambulatory Surgical Center Adoption

5. Innovation & Pipeline Landscape

5.1 Innovation Landscape Overview
- 5.1.1 Evolution of Coronary Angioplasty Technologies
- 5.1.2 Emerging Interventional Cardiology Platforms
- 5.1.3 AI and Digital Integration in PCI
5.2 Pipeline Analysis by Product Type
- 5.2.1 Drug-Eluting Stents (DES)
- 5.2.2 Drug-Coated Balloons (DCB)
- 5.2.3 Bioabsorbable Vascular Scaffolds
- 5.2.4 Intravascular Lithotripsy Systems
- 5.2.5 Robotic-Assisted PCI Platforms
5.3 Pipeline Analysis by Development Stage
- 5.3.1 Commercialized Technologies
- 5.3.2 Phase III Technologies
- 5.3.3 Phase II Technologies
- 5.3.4 Early-Stage and Feasibility Programs
5.4 Pipeline Analysis by Mechanism and Modality
- 5.4.1 Sirolimus-Eluting Technologies
- 5.4.2 Everolimus-Eluting Technologies
- 5.4.3 Paclitaxel-Coated Devices
- 5.4.4 Magnesium-Based Scaffolds
- 5.4.5 Calcium Modification Technologies
5.5 Clinical Trial Landscape
- 5.5.1 PCI Clinical Trial Trends
- 5.5.2 Endpoint Analysis
- 5.5.3 Safety and Efficacy Benchmarking
- 5.5.4 Trial Design Trends
5.6 Patent and Intellectual Property Analysis
- 5.6.1 Stent Technology Patent Landscape
- 5.6.2 Imaging and Navigation Patents
- 5.6.3 Expiring Patent Analysis

6. Treatment Landscape

6.1 Current Treatment Paradigm
- 6.1.1 Medical Management
- 6.1.2 Percutaneous Coronary Intervention
- 6.1.3 Coronary Artery Bypass Grafting (CABG)
6.2 Coronary Angioplasty Procedure Workflow
- 6.2.1 Diagnostic Coronary Angiography
- 6.2.2 Balloon Angioplasty
- 6.2.3 Stent Placement Procedures
- 6.2.4 Imaging-Guided PCI
- 6.2.5 Post-Procedure Monitoring
6.3 Device Landscape
- 6.3.1 Balloon Catheters
- 6.3.2 Drug-Eluting Stents
- 6.3.3 Bare-Metal Stents
- 6.3.4 Drug-Coated Balloons
- 6.3.5 Guidewires
- 6.3.6 Atherectomy Systems
- 6.3.7 Intravascular Imaging Systems
6.4 Adjunct Pharmacotherapy Landscape
- 6.4.1 Antiplatelet Therapy
- 6.4.2 Anticoagulants
- 6.4.3 Lipid-Lowering Therapies
- 6.4.4 Glycoprotein IIb/IIIa Inhibitors
6.5 Technology Assessment
- 6.5.1 Optical Coherence Tomography (OCT)
- 6.5.2 Intravascular Ultrasound (IVUS)
- 6.5.3 Fractional Flow Reserve (FFR)
- 6.5.4 Coronary Physiology Assessment Tools

7. Global Coronary Angioplasty Market Size & Forecast

7.1 Global Market Overview
- 7.1.1 Historical Market Size Analysis
- 7.1.2 Forecast Methodology
- 7.1.3 Market Forecast (2026-2031)
- 7.1.4 CAGR Analysis
7.2 Market Forecast by Product Type
- 7.2.1 Balloon Catheters
- 7.2.2 Drug-Eluting Stents
- 7.2.3 Bare-Metal Stents
- 7.2.4 Drug-Coated Balloons
- 7.2.5 Imaging and Physiology Devices
- 7.2.6 Atherectomy Systems
7.3 Market Forecast by Indication
- 7.3.1 Stable Coronary Artery Disease
- 7.3.2 Acute Coronary Syndrome
- 7.3.3 Chronic Total Occlusion
- 7.3.4 Left Main Coronary Disease
7.4 Market Forecast by End User
- 7.4.1 Hospitals
- 7.4.2 Specialty Cardiac Centers
- 7.4.3 Ambulatory Surgical Centers

8. Global Coronary Angioplasty Market Segmentation

8.1 By Product Type
- 8.1.1 Balloon Angioplasty Catheters
- 8.1.2 Stents
  - 8.1.2.1 Drug-Eluting Stents
  - 8.1.2.2 Bare-Metal Stents
  - 8.1.2.3 Others
- 8.1.4 Guidewires
- 8.1.5 Others
8.2 By Indication
- 8.2.1 Coronary Artery Disease
- 8.2.2 Chronic Total Occlusion
- 8.2.3 Others
8.3 By End User
- 8.3.1 Hospitals & Clincs
- 8.3.2 Ambulatory Surgical Centers
- 8.3.3 Others

9. Geographical Analysis (Regional Level)

9.1 North America
- 9.1.1 Market Size and Forecast
- 9.1.2 Key Growth Drivers
- 9.1.3 Regulatory Overview
- 9.1.4 Competitive Landscape
9.2 Europe
- 9.2.1 Market Size and Forecast
- 9.2.2 Demand and Adoption Trends
- 9.2.3 MDR Regulatory Environment
- 9.2.4 Competitive Intensity
9.3 Asia-Pacific
- 9.3.1 Market Size and Forecast
- 9.3.2 Expansion of Interventional Cardiology Infrastructure
- 9.3.3 Regulatory Environment
- 9.3.4 Competitive Dynamics
9.4 Latin America
- 9.4.1 Market Size and Forecast
- 9.4.2 Healthcare Infrastructure Trends
- 9.4.3 Regulatory Environment
- 9.4.4 Competitive Analysis
9.5 Middle East & Africa
- 9.5.1 Market Size and Forecast
- 9.5.2 Cardiovascular Disease Burden
- 9.5.3 Regulatory Environment
- 9.5.4 Market Competition Assessment

10. Key Countries Analysis

10.1 United States
- 10.1.1 Market Size Analysis
- 10.1.2 CAD Epidemiology
- 10.1.3 FDA Regulatory Framework
- 10.1.4 Reimbursement Landscape
- 10.1.5 Key Companies and Products Presence
10.2 Canada
- 10.2.1 Market Size Analysis
- 10.2.2 Epidemiology Overview
- 10.2.3 Regulatory Framework
- 10.2.4 Reimbursement Analysis
- 10.2.5 Competitive Presence
10.3 Germany
- 10.3.1 Market Size Analysis
- 10.3.2 Epidemiology Overview
- 10.3.3 MDR and National Regulatory Framework
- 10.3.4 Reimbursement Landscape
- 10.3.5 Key Market Participants
10.4 United Kingdom
- 10.4.1 Market Size Analysis
- 10.4.2 CAD Burden Assessment
- 10.4.3 MHRA Regulatory Framework
- 10.4.4 NHS Reimbursement Environment
- 10.4.5 Company Presence
10.5 France
- 10.5.1 Market Size Analysis
- 10.5.2 Epidemiology Trends
- 10.5.3 Regulatory Environment
- 10.5.4 Reimbursement Framework
- 10.5.5 Key Products Availability
10.6 Italy
- 10.6.1 Market Size Analysis
- 10.6.2 CAD Epidemiology
- 10.6.3 Regulatory Structure
- 10.6.4 Reimbursement Environment
- 10.6.5 Competitive Analysis
10.7 Spain
- 10.7.1 Market Size Analysis
- 10.7.2 Disease Burden Analysis
- 10.7.3 Regulatory Overview
- 10.7.4 Reimbursement Trends
- 10.7.5 Key Market Players
10.8 China
- 10.8.1 Market Size Analysis
- 10.8.2 CAD Epidemiology
- 10.8.3 NMPA Regulatory Framework
- 10.8.4 Pricing and Reimbursement
- 10.8.5 Domestic and International Company Presence
10.9 Japan
- 10.9.1 Market Size Analysis
- 10.9.2 Epidemiology Assessment
- 10.9.3 PMDA Regulatory Framework
- 10.9.4 Reimbursement Structure
- 10.9.5 Key Products and Companies
10.10 India
- 10.10.1 Market Size Analysis
- 10.10.2 Coronary Disease Burden
- 10.10.3 CDSCO Regulatory Framework
- 10.10.4 Pricing Regulations and Reimbursement
- 10.10.5 Domestic Manufacturing Landscape
10.11 South Korea
- 10.11.1 Market Size Analysis
- 10.11.2 Epidemiology Overview
- 10.11.3 MFDS Regulatory Framework
- 10.11.4 Reimbursement Trends
- 10.11.5 Competitive Assessment
10.12 Australia
- 10.12.1 Market Size Analysis
- 10.12.2 CAD Epidemiology
- 10.12.3 TGA Regulatory Framework
- 10.12.4 Reimbursement Landscape
- 10.12.5 Market Participants
10.13 Brazil
- 10.13.1 Market Size Analysis
- 10.13.2 Epidemiology Overview
- 10.13.3 ANVISA Regulatory Framework
- 10.13.4 Reimbursement Trends
- 10.13.5 Competitive Environment
10.14 Mexico
- 10.14.1 Market Size Analysis
- 10.14.2 Disease Burden Overview
- 10.14.3 COFEPRIS Regulatory Framework
- 10.14.4 Reimbursement Analysis
- 10.14.5 Market Presence
10.15 Saudi Arabia
- 10.15.1 Market Size Analysis
- 10.15.2 Cardiovascular Disease Trends
- 10.15.3 SFDA Regulatory Framework
- 10.15.4 Reimbursement Environment
- 10.15.5 Company Presence
10.16 South Africa
- 10.16.1 Market Size Analysis
- 10.16.2 Epidemiology Overview
- 10.16.3 SAHPRA Regulatory Framework
- 10.16.4 Reimbursement Structure
- 10.16.5 Market Competition

11. Regulatory & Policy Landscape

11.1 United States Regulatory Landscape
- 11.1.1 FDA Device Approval Pathways
- 11.1.2 PMA and 510(k) Processes
- 11.1.3 UDI and Post-Market Surveillance
11.2 Europe Regulatory Landscape
- 11.2.1 European Medical Device Regulation (MDR)
- 11.2.2 CE Marking Requirements
- 11.2.3 Post-Market Clinical Follow-Up
11.3 Japan Regulatory Landscape
- 11.3.1 PMDA Approval Framework
- 11.3.2 Device Classification System
- 11.3.3 Reimbursement Integration
11.4 India Regulatory Landscape
- 11.4.1 CDSCO Medical Device Regulations
- 11.4.2 Price Control Mechanisms
- 11.4.3 Import and Manufacturing Requirements
11.5 China Regulatory Landscape
- 11.5.1 NMPA Approval Pathways
- 11.5.2 Volume-Based Procurement Policies
- 11.5.3 Local Manufacturing Regulations
11.6 International Standards and Guidelines
- 11.6.1 ISO Standards for Cardiovascular Devices
- 11.6.2 Clinical Evaluation Requirements
- 11.6.3 Adverse Event Reporting Systems

12. Competitive Landscape

12.1 Market Share Analysis
- 12.1.1 Global Market Share by Company
- 12.1.2 Market Share by Product Category
12.2 Competitive Benchmarking
- 12.2.1 Product Portfolio Benchmarking
- 12.2.2 Technology Comparison
- 12.2.3 Pricing Benchmarking
- 12.2.4 Geographic Presence Analysis
12.3 Strategic Developments
- 12.3.1 Mergers and Acquisitions
- 12.3.2 Partnerships and Collaborations
- 12.3.3 Product Launches
- 12.3.4 Regulatory Approvals
- 12.3.5 Manufacturing Expansion
12.4 SWOT Analysis
- 12.4.1 Leading Company SWOT Assessment
- 12.4.2 Emerging Competitor SWOT Assessment

13. Company Profiles

13.1 Abbott Laboratories
- 13.1.1 Company Overview
- 13.1.2 Coronary Angioplasty Product Portfolio
- 13.1.3 XIENCE Drug-Eluting Stents
- 13.1.4 NC TREK and Balloon Catheter Portfolio
- 13.1.5 Key Indications
- 13.1.6 Pipeline and Innovation Programs
13.2 Boston Scientific Corporation
- 13.2.1 Company Overview
- 13.2.2 SYNERGY Drug-Eluting Stent System
- 13.2.3 AGENT Drug-Coated Balloon
- 13.2.4 Imaging and Coronary Physiology Portfolio
- 13.2.5 Pipeline Programs
13.3 Medtronic plc
- 13.3.1 Company Overview
- 13.3.2 Resolute Onyx Drug-Eluting Stent
- 13.3.3 Prevail Drug-Coated Balloon
- 13.3.4 Coronary Balloon Catheter Portfolio
- 13.3.5 Pipeline and Clinical Programs
13.4 Terumo Corporation
- 13.4.1 Company Overview
- 13.4.2 Ultimaster Drug-Eluting Stent
- 13.4.3 Guidewire and Catheter Portfolio
- 13.4.4 Interventional Cardiology Expansion Strategy
- 13.4.5 Pipeline Technologies
13.5 BIOTRONIK
- 13.5.1 Company Overview
- 13.5.2 Orsiro Drug-Eluting Stent
- 13.5.3 Coronary Imaging and PCI Portfolio
- 13.5.4 Clinical Evidence and Trials
- 13.5.5 Pipeline Innovations
13.6 B. Braun
- 13.6.1 Company Overview
- 13.6.2 SeQuent Please Drug-Coated Balloon
- 13.6.3 Coronary Angioplasty Catheter Portfolio
- 13.6.4 Key Indications
- 13.6.5 Pipeline Programs
13.7 Shockwave Medical
- 13.7.1 Company Overview
- 13.7.2 Shockwave C2 Coronary IVL System
- 13.7.3 Coronary Calcium Modification Technologies
- 13.7.4 Clinical Trial Programs
- 13.7.5 Growth Strategy
13.8 Teleflex Incorporated
- 13.8.1 Company Overview
- 13.8.2 GuideLiner Catheter Portfolio
- 13.8.3 Interventional Access Products
- 13.8.4 Clinical Applications
- 13.8.5 Pipeline Developments
13.9 Asahi Intecc Co., Ltd.
- 13.9.1 Company Overview
- 13.9.2 Coronary Guidewire Portfolio
- 13.9.3 CTO Intervention Solutions
- 13.9.4 Global Expansion Strategy
- 13.9.5 Pipeline Technologies
13.10 Philips
- 13.10.1 Company Overview
- 13.10.2 IntraSight Imaging and Physiology System
- 13.10.3 IVUS and FFR Portfolio
- 13.10.4 Image-Guided Therapy Strategy
- 13.10.5 Pipeline and Innovation Initiatives

14. Future Outlook

14.1 Future Market Trends
- 14.1.1 Transition Toward Precision PCI
- 14.1.2 AI-Enabled Coronary Intervention
- 14.1.3 Growth of Imaging-Guided PCI
- 14.1.4 Evolution of Bioabsorbable Technologies
14.2 Emerging Opportunities
- 14.2.1 Emerging Market Expansion
- 14.2.2 Ambulatory PCI Adoption
- 14.2.3 Personalized Antiplatelet Strategies
- 14.2.4 Robotic PCI Expansion
14.3 Analyst Recommendations
- 14.3.1 Strategic Priorities for Manufacturers
- 14.3.2 Investment Hotspots
- 14.3.3 Technology Development Priorities
- 14.3.4 Market Entry Recommendations

15. Methodology

15.1 Research Methodology
- 15.1.1 Primary Research
- 15.1.2 Secondary Research
- 15.1.3 Data Validation and Triangulation
15.2 Market Estimation Methodology
- 15.2.1 Top-Down Approach
- 15.2.2 Bottom-Up Approach
- 15.2.3 Forecast Modeling Techniques
15.3 Data Sources
- 15.3.1 Regulatory Databases
- 15.3.2 Company Annual Reports
- 15.3.3 Clinical Trial Registries
- 15.3.4 Peer-Reviewed Publications
- 15.3.5 Industry Associations and Databases
15.4 Assumptions and Limitations
- 15.4.1 Market Assumptions
- 15.4.2 Currency Conversion Assumptions
- 15.4.3 Limitations of Research Scope